Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann HGrading strength of recommendations and quality of evidence in clinical guidelines. Chest 129(1): 174-181

Department of Medicine, HSC-2C12, McMaster University, 1200 Main St West, Hamilton, ON, Canada L8N 3Z5.
Chest (Impact Factor: 7.48). 02/2006; 129(1):174-81. DOI: 10.1378/chest.129.1.174
Source: PubMed


While grading the strength of recommendations and the quality of underlying evidence enhances the usefulness of clinical guidelines, the profusion of guideline grading systems undermines the value of the grading exercise. An American College of Chest Physicians (ACCP) task force formulated the criteria for a grading system to be utilized in all ACCP guidelines that included simplicity and transparency, explicitness of methodology, and consistency with current methodological approaches to the grading process. The working group examined currently available systems, and ultimately modified an approach formulated by the international GRADE group. The grading scheme classifies recommendations as strong (grade 1) or weak (grade 2), according to the balance among benefits, risks, burdens, and possibly cost, and the degree of confidence in estimates of benefits, risks, and burdens. The system classifies quality of evidence as high (grade A), moderate (grade B), or low (grade C) according to factors that include the study design, the consistency of the results, and the directness of the evidence. For all future ACCP guidelines, The College has adopted a simple, transparent approach to grading recommendations that is consistent with current developments in the field. The trend toward uniformity of approaches to grading will enhance the usefulness of practice guidelines for clinicians.

Download full-text


Available from: Doreen addrizzo-harris, Oct 11, 2014
1 Follower
53 Reads
  • Source
    • "Malignant pleural mesothelioma (MPM) is a highly aggressive tumour, which is linked to prior exposure to asbestos with a latency period of 20–30 years in approximately 80% of all cases (Weill et al, 2004; Hazarika et al, 2005; Goudar, 2008). Systemic therapy represents the primary treatment option for most patients (Treasure and Sedrakyan, 2004; Tsao et al, 2009), but standard MPM therapy is still deficient and decisions for radiotherapy, surgery or combined approaches are based on a case-by-case decision leading to a palliative treatment approach for most patients (Guyatt et al, 2006; Muers et al, 2008; Stahel et al, 2009; Astoul et al, 2012). Gender, histological subtype and haematological parameters have been identified as important prognostic parameters (Flores et al, 2007; Rusch et al, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumour that is first-line treated with a combination of cisplatin and pemetrexed. Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. P53 is frequently inactivated in MPM, but mutations are extremely rare. MDM2 and P14/ARF are upstream regulators of P53 that may contribute to P53 inactivation. Methods: A total of 72 MPM patients were investigated. MDM2 immunoexpression was assessed in 65 patients. MDM2 and P14/ARF mRNA expression was analysed in 48 patients of the overall collective. The expression results were correlated to overall survival (OS) and progression-free survival (PFS). Results: OS and PFS correlated highly significantly with MDM2 mRNA and protein expression, showing a dismal prognosis for patients with elevated MDM2 expression (for OS: Score (logrank) test: P⩽0.002, and for PFS: Score (logrank) test; P<0.007). MDM2 was identified as robust prognostic and predictive biomarker for MPM on the mRNA and protein level. P14/ARF mRNA expression reached no statistical significance, but Kaplan-Meier curves distinguished patients with low P14/ARF expression and hence shorter survival from patients with higher expression and prolonged survival. Conclusions: MDM2 is a prognostic and predictive marker for a platin-pemetrexed therapy of patients with MPMs. Downregulation of P14/ARF expression seems to contribute to MDM2-overexpression-mediated P53 inactivation in MPM patients.
    British Journal of Cancer 02/2015; 112(5). DOI:10.1038/bjc.2015.27 · 4.84 Impact Factor
  • Source
    • "Supplementary Table 1 lists all members of the ABC2 consensus panel and their disclosure of any relationships that could be perceived as a potential conflict of interest. Table 1 describes the grading system used [15]. Three main issues were discussed at ABC2: inoperable locally advanced breast cancer (LABC) both inflammatory and noninflammatory ; MBC; and specific definitions for which a consensus was deemed important. "
    The Breast 09/2014; 23(5):489-502. DOI:10.1016/j.breast.2014.08.009. · 2.38 Impact Factor
  • Source
    • "Using the criteria defined by the American College of Chest Physicians (ACCP), each form of intervention was attributed a recommendation grade where appropriate. For further details on the criteria, please refer to Table 1[12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Frostbite presentation to hospital is relatively infrequent, and the optimal management of the more severely injured patient requires a multidisciplinary integration of specialist care. Clinicians with an interest in wilderness medicine/freezing cold injury have the awareness of specific potential interventions but may lack the skill or experience to implement the knowledge. The on-call specialist clinician (vascular, general surgery, orthopaedic, plastic surgeon or interventional radiologist), who is likely to receive these patients, may have the skill and knowledge to administer potentially limb-saving intervention but may be unaware of the available treatment options for frostbite. Over the last 10 years, frostbite management has improved with clear guidelines and management protocols available for both the medically trained and winter sports enthusiasts. Many specialist surgeons are unaware that patients with severe frostbite injuries presenting within 24 h of the injury may be good candidates for treatment with either TPA or iloprost. In this review, we aim to give a brief overview of field frostbite care and a practical guide to the hospital management of frostbite with a stepwise approach to thrombolysis and prostacyclin administration for clinicians.
    04/2014; 3:7. DOI:10.1186/2046-7648-3-7
Show more